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Abstract: Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically signifi cant agent for which 
there currently are no effective treatments. Development of antiviral agents for PRRSV as well as many other viruses has 
been limited by toxicity of known antiviral compounds. In contrast, antibiotics for non-virus microbial infections have been 
widely useful, in part because of their acceptable toxicity in animals. We report here the discovery that the quinolone-
containing compound Plasmocin™, as well as the quinolones nalidixic acid and ciprofl oxacin, have potent anti-PRRSV 
activity in vitro. PRRSV replication was inhibited by these antibiotics in both cultured MARC-145 cells and cultured primary 
alveolar porcine macrophages (PAMs). Furthermore, sub-optimal concentrations of nalidixic acid synergized with antiviral 
cytokines (AK-2 or IFN-γ) to quantitatively and qualitatively inhibit PRRSV replication in MARC-145 cells or PAMs.
The antiviral activity of Plasmocin and nalidixic acid correlated with reduced actin expression in MARC-145 cells. Repli-
cation of the related lactate dehydrogenase-elevating virus (LDV) was also inhibited in primary mouse macrophages by 
Plasmocin. These results are signifi cant to the development of antiviral strategies with potentially reduced toxicity, and 
provide a model system to better understand regulation of arterivirus replication.
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Introduction
Antimicrobial agents used to treat bacterial or fungal infections generally interfere with specifi c processes 
that are essential for microbe growth and/or division, for example cell wall synthesis, cytoplasmic membrane 
function, nucleic acid synthesis, or ribosome function (Neu and Gootz, 1996). On the other hand, antiviral 
chemotherapy may target the cells supporting virus replication as well as events specifi c to the virus, with 
potentially toxic side effects (De Clerq, 1996). Toxicity to the host is also well known for some antibiotics, 
including hematologic suppression, kidney and liver injury due to metabolism in those organs, as well as 
neurological side effects (Snavely and Hodges, 1984; Neu and Gootz, 1996; Chow et al. 2004), demonstrat-
ing the potential for direct host effects of antibiotics. The mechanisms of antibiotic toxicity in mammals 
are not well understood, but may include enzyme or membrane alterations as well as induction of apopto-
sis (Gerbaux et al. 1996; Van Bambeke et al. 1998; El Mouedden et al. 2000; Sliva and Schnierle, 2007).
Previous studies have demonstrated that in some cases, antibiotics may have antiviral effects (Subak-
Sharpe et al.1969; Macintyre et al. 1991), most likely due to inhibition of host cell functions required 
for viral replication. For the present study, several antibiotics were screened for effects on porcine 
reproductive and respiratory syndrome virus (PRRSV) in vitro. PRRSV is the etiologic agent of an 
economically-important porcine disease (PRRS; Albina et al. 1997; Prieto et al. 2005) and is also a 
model for chronic virus infection. The mechanism of chronic PRRSV infection is unclear. The virus 
induces several cytokines including interferon-gamma (IFN-γ), which inhibits PRRSV replication in 
vitro (Aasted et al. 2002; Cafruny et al. 2006; Johnsen et al. 2002; Rowland et al. 2001). However, the 
IFN-γ response in pigs may be delayed or inhibited by unknown factors, and a poorly-neutralizing Th2 
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response may also contribute to virus persistence 
(Meier et al. 2003; Meier et al. 2004). PRRSV, and 
the related lactate dehydrogenase-elevating virus 
(LDV) of mice, are resistant to vaccination strate-
gies, and antivirals for PRRSV are still in an early 
stage of development. We show that several qui-
nolone-containing compounds have potent anti-
PRRSV effects, which correlated with inhibition 
of actin expression in MARC-145 cells. Further-
more, quinolone treatment was found to potentiate 
the cytokine-mediated inhibition of PRRSV repli-
cation in MARC-145 cells and in primary pig 
macrophages. These novel drug effects may pro-
vide insights into mechanisms of viral replication 
as well as the development of future therapeutic 
agents for virus infection.
Materials and Methods
Target cells for virus replication
PRRSV was inoculated on monolayer cultures of 
a mycoplasma-free MARC-145 cell line (Kim et al. 
1993; Meulenberg, 2000) or on primary alveolar 
pig macrophages (Oleksiewicz, M.B., Nielsen, J. 
1999). The MARC-145 cells were routinely pas-
saged in DMEM containing 10% fetal bovine 
serum, and for virus infections the medium was 
switched to MEM containing 2% horse serum. 
MARC-145 cells for virus infections were grown 
for 1–2 days in 8-well glass slide chambers (~30–
40,000 confl uent cells/culture; Lab-Tek II; Nalge 
Nunc International, as described (Cafruny et al. 
2006). Pig cells were collected from 4–8 week old 
pigs by lung lavage with PBS (Mengeling et al. 
1995; Duan et al. 1997; Oleksiewicz et al. 1999) 
and stored at −70 °C. Vials of these cells were 
rapidly thawed, centrifuged for 5 min at 1000 × G 
to obtain a cell pellet, which was resuspended in 
DMEM containing 10% fetal bovine serum. The 
cells were then distributed into wells of 8-well slide 
chambers, and after about 18 h of incubation at 
37 °C, non-adherent cells were removed, and the 
adherent cells (primary alveolar porcine macro-
phages or PAMs) were incubated for an additional 
4–6 h prior to PRRSV inoculation. Typically there 
were about 10,000–20,000 PAMs per culture well, 
with variation noted between experiments but not 
within a given experiment, suggesting that the 
variation was due to differences among the 
collected aliquots of alveolar cells. For LDV 
infection, primary mouse (outbred CF1) peritoneal 
macrophages were established in 8-well glass slide 
chambers, and inoculated with LDV within 24 h 
as described previously (Plagemann and Moennig, 
1992; Cafruny et al. 2006).
Viruses and virus infections
MARC-145 cells were infected with the PRRSV 
isolate SD-23983, preparing high-titer (~106 
TCID50 per ml) virus stocks from the culture super-
natants of 48–96 h p.i. MARC-145 cells. For the 
experiments described, MARC-145 cells were 
inoculated with an MOI of about 0.1 TCID50 and 
PAMs with an MOI of about 0.5 TCID50 which are 
approximately optimal for these systems (Rowland 
et al. 2001; Kim et al. 2002; Cafruny et al. 2006). 
LDV-P stocks were prepared as previously 
described and used to inoculate mouse macrophage 
cultures with an MOI of about 1000 (Plagemann 
and Moennig, 1992).
Drugs and drug treatments
Plasmocin™ (product of Cayla, www.cayla.com; 
distributed by Invivogen; ant-mpt), nalidixic acid 
(Sigma; N5035), ciprofloxacin (Biochemika; 
17850), erythromycin (Amresco; 0219-10G), 
penicillin (Sigma; P3032) and streptomycin 
(Sigma; S9137) were used as sterile preparations 
at various concentrations (2.5–250 ug/ml) as indi-
cated in the Results. The recombinant human 
antiviral cytokines AK-2 (50 ug/ml) and interferon-
γ (IFN-γ; 100 ug/ml) were generated by Actokine 
Therapeutics and used as previously described 
(Cafruny et al. 2006). AK-2 is a cytokine-based 
experimental antiviral being developed by Acto-
kine Therapeutics, which consists of recombinant 
normal human proteins comprising part of the 
mammalian cell response to virus infection (Wong 
et al. unpublished; Cafruny et al. 2006).
Fluorescence (FA) detection of virus 
replication and actin expression
PRRSV replication was detected using FITC-
labeled IgG anti-PRRSV nucleocapsid antibodies 
(SDOW17; Nelson et al. 1993). MARC-145 cells 
or primary alveolar porcine macrophages (PAMs) 
were fi xed in 80% acetone, and incubated for 1 h 
at 37 °C with a 1:100 dilution of FITC-conjugated 
SDOW17 antibody made in PBS containing 5% 
fetal bovine serum. The fi xed PAMS were blocked 
with 5% heat-inactivated normal mouse plasma 
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for 30 min prior to incubation with SDOW17, and 
in some experiments incubation of PAMs with 
SDOW17 was for 3 h at room temperature. Actin 
was stained using 592-phalloidin as described 
previously (Cafruny et al. 2006). After incubation 
with the fl uorescence antibody reagents, the cells 
were washed three times with cold PBS prior to 
examination by confocal fl uorescence microscopy, 
using an Olympus BX61 microscope and Fluoview 
software. Quantitative analyses were performed 
by directly counting fl uorescence-positive cells in 
experimental and control wells. Multiple experi-
ments were analyzed as shown in the results; the 
representative images shown in the fi gures were 
obtained at equivalent PMT settings within each 
experiment, and display small scale bars as identi-
fi ed in the fi gure captions. LDV replication was 
determined in primary mouse macrophages as 
described previously (Cafruny et al. 1986), count-
ing the total LDV antigen-positive cells per culture 
under a fl uorescence microscope.
Cytotoxicity testing
The cells used for these experiments exhibited high 
(99%; Table 4) viability. Potential cytotoxicity 
of the antiviral drugs was assessed by trypan blue 
dye-exclusion (Freshney, 1987). After a period of 
drug exposure (Table 4), cell cultures were washed 
once with PBS and then incubated with 0.4% try-
pan blue for 5 min at room temperature. Dead cells 
were counted under a light microscope and com-
parison made between drug-treated and untreated 
control cultures. The cells were then fi xed and 
stained with crystal violet, and quantitatively 
assessed under the microscope to provide an esti-
mate of total-cell counts under the different culture 
conditions. Based on this method, the drug 
responses reported here did not correlate with 
detectable cytoxicity (see below and Table 4).
Results
Inhibition of PRRSV replication 
in MARC-145 cells by quinolone-
containing antibiotics
The fi rst indication that some antibiotics were 
capable of inhibiting PRRSV replication emerged 
from studies with Plasmocin, a proprietary agent 
consisting of quinolone and macrolide antibiotics 
which has potent anti-mycoplasma activity. 
Treament of MARC-145 cells with Plasmocin was 
found to inhibit PRRSV replication in a dose- and 
time-dependent fashion, as shown in Table 1 
A,C,D. Figure 1A illustrates the antiviral effect of 
Plasmocin added at the time of virus inoculation, 
which almost completely abrogated PRRSV-per-
missiveness in MARC-145 cells, with a total of 
only 20 weakly-PRRSV-positive cells in two 
treated cultures, versus a mean of 458 +/− 40 
PRRSV-positive cells in control cultures. In con-
trast, addition of Plasmocin at 3 or 6 h p.i. resulted 
in progressively weaker antiviral effects (Fig. 1A 
and Table 1).
PRRSV replication in MARC-145 cells was 
also inhibited by the quinolones nalidixic acid and 
ciprofl oxacin (Table 1B and C). The dose- and 
time-dependency of the nalidixic acid response are 
shown in Table 1B and C. In contrast, neither 
erythromycin (a representative macrolide) nor the 
combination of penicillin (150 ug/ml) and strep-
tomycin (200 ug/ml) had any signifi cant effect on 
PRRSV replication in MARC-145 cells (Table 1E 
and F, and Fig. 1C). Combined, these data show 
that an early stage of PRRSV replication is inhib-
ited by quinolone antibiotics or quinolone-
containing compounds.
Cytotoxicity testing was carried out by trypan 
blue dye exclusion and total cell count analyses. 
No cytotoxicity of the antibiotics studied was 
observed in MARC-145 cells under our experi-
mental conditions (Table 4). Furthermore, con-
tinuous treatment of MARC-145 cells for 2 weeks 
with 25 ug/ml Plasmocin had no detectable effect 
on cell propagation or viability (Duman et al. 
unpublished).Thus, the viral responses appear 
unrelated to general cytotoxicity.
Inhibition of PRRSV replication 
in primary alveolar porcine 
macrophages (PAMs) by plasmocin 
and nalidixic acid
Virus responses to Plasmocin and nalidixic acid 
were similar in primary alveolar porcine macro-
phages (PAMs) from several different pigs to those 
seen in MARC-145 cells (Table 2). While there 
were some variations in the magnitudes of the 
antiviral responses, both Plasmocin and nalidixic 
acid were potent antivirals in cultured PAMs, 
whereas an antiviral effect of erythromycin was 
not noted. The source of the variation we observed 
is not known, but could be due to differences 
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between pigs or among vials of cells obtained from 
the same pig. Cytotoxicity studies demonstrated 
occasional reduction in total cell numbers and/or 
enhanced uptake of trypan blue at the highest 
Plasmocin concentration (250 ug/ml), but neither 
nalidixic acid nor Plasmocin at lower but effective 
concentrations appeared to be cytotoxic to PAMs 
by these methods (Table 4). Figure 1B illustrates 
the antiviral effect of 25 ug/ml Plasmocin in PAMs. 
Additional PAM responses to antibiotics are 
described below.
Correlation of quinolone-mediated 
inhibition of PRRSV replication 
with reduced actin expression
Previous studies showed that PRRSV replication 
is dependent on an intact cytoskeletion and 
is inhibited by the actin-disrupting agent 
cytochalasin D (Cafruny et al. 2006). As illustrated 
in Figure 1D, actin expression was reduced in 
cultured MARC-145 cells by both Plasmocin and 
nalidixic acid, but little effect of erythromycin on 
actin expression was observed. Inhibition of actin 
expression by Plasmocin and nalidixic acid was 
dose-dependent (data not shown).
Potentiation of cytokine-mediated 
inhibition of PRRSV replication 
by nalidixic acid
AK-2 and IFN-γ are potent inhibitors of LDV and 
PRRSV replication, establishing an antiviral state 
in MARC-145 cells, as well as primary pig and 
mouse macrophages (Cafruny et al. 2006). For the 
present study, sub-optimal concentrations (below 
Table 1. Antibiotic-mediated inhibition of PRRSV replication in MARC-145 cells.
Expt. Drug treatment1 Percent of PRRSV- 
 positive
 cells relative to control
A. Plasmocin dose response (drug at T = 0 h p.i.) 
   Plasmocin 250 ug/ml 0
   Plasmocin 25 ug/ml 53
   Plasmocin 2.5 ug/ml 73
B. Nalidixic acid dose response (drug at T = 0 h p.i.) 
   Nalidixic acid 125 ug/ml 0
   Nalidixic acid 25 ug/ml 64
   Nalidixic acid 12.5 ug/ml 103
C. PRRSV inhibition by time of addition 
   Plasmocin 125 ug/ml T = 0 h p.i. 11
   Plasmocin 125 ug/ml T = 5 h p.i. 72
   Nalidixic acid 125 ug/ml T = 0 h p.i. 1
   Nalidixic acid 125 ug/ml T = 5 h p.i. 6
   Ciprofl oxacin 125 ug/ml T = 0 h p.i. 18
   Ciprofl oxacin 125 ug/ml T = 5 h p.i. 61
D. PRRSV inhibition reduced by post-treatment 
   Plasmocin 125 ug/ml T = 0 h p.i. 2
   Plasmocin 125 ug/ml T = 3 h p.i. 13
   Plasmocin 125 ug/ml T = 6 h p.i. 66
E. Weak or no PRRSV inhibition by erythromycin (mean of 2 expts.) 
   Erythromycin 250 ug/ml 85
   Erythromycin 125 ug/ml 110
   Erythromycin 62 ug/ml 125
   Erythromycin 31 ug/ml 104
F. Penicillin/streptomycin: no effect on PRRSV replication 
   Pen 150 ug/ml and strep 200 ug/ml 94
   Pen 150 ug/ml and strep 200 ug/ml 114
   Pen 150 ug/ml and strep 200 ug/ml 99
   Pen 150 ug/ml and strep 200 ug/ml 92
1Drug dose and time of addition are indicated; for C, drugs were added at the time of virus inoculation (T = 0 h p.i.) or at 5 h p.i. (T = 5 h p.i.). 
Percent results are derived from means of duplicate wells, with 20% variation between well counts. For A-D, dose- and time-dependent 
antiviral effects of the antibiotics were apparent, and only the 12.5 ug/ml dose of nalidixic acid failed to show at least some antiviral activity.
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the concentrations with maximum antiviral activity 
(Cafruny et al. 2006, and Tables 1 and 2) of these 
cytokines as well as nalidixic acid (25 ug/ml) 
were used to treat cultured MARC-145 cells or 
primary alveolar pig macrophages (PAMs) just 
prior to or at the time of PRRSV inoculation. In 
most experiments, the drugs were used for 5 h 
pretreatment only, and after drug-removal, the cells 
were inoculated with PRRSV, fi xed at about 14 h 
p.i, and stained for PRRSV antigen expression. 
Suboptimal concentrations of nalidixic acid, in 
some cases below the threshold of detectable 
antiviral effect by pretreatment, were found to 
synergize with low levels of AK-2 or IFN-γ, to 
inhibit PRRSV replication, as shown in Table 3. 
In experiment #1, the combined drug effect 
appeared to be additive, but in most of the 
experiments actual potentiation was observed since 
A. Time course of MARC-145 cell response to 125 ug/ml Plasmocin 
Control (458 +/−40)                            Drug at T = 0 h p.i. (10 +/−3)        
Drug at T = 3 h p.i. (58 +/−2)              Drug at T = 6 h p.i. (302 +/−37) 
B. Inhibition of PRRSV replication in primary pig macrophages 
Control                                                   Plasmocin 25 ug/ml 
22
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the nalidixic acid concentration was below an 
effective threshold. The drug effects were not due 
to detectable cytotoxicity (Table 4) or loss of total 
cells due to drug exposure. Figure 2A illustrates 
these viral responses to sub-optimal quinolone and 
cytokine concentrations, and Figure 2B illustrates 
partial (reduced intensity and scope of PRRSV 
antigen) antiviral responses which were observed 
in some cells due to combination drug treatment 
at sub-optimal concentrations.
Figure 1. Inhibition of PRRSV replication in cultured MARC-145 cells and in primary alveolar porcine macrophages (PAMs) by Plas-
mocin, and correlation of the quinolone antiviral effect with inhibition of actin expression in MARC-145 cells.
A. Time course of the antiviral response to 125 ug/ml Plasmocin (numbers in parentheses are mean +/− SD PRRSV-positive cells/culture). 
B. Inhibition of PRRSV replication in PAMs by 25 ug/ml Plasmocin. C. No effect of penicillin and streptomycin on PRRSV replication in MARC-
145 cells. D. Antiviral effects of Plasmocin and nalidixic acid correlate with inhibition of actin expression in MARC-145 cells. Scale bars = 
100 um (A); 20 um (B); 100 um (C); 50 um (D).
C. No effect of penicillin or streptomycin on PRRSV replication 
No antibiotics                                  Penicillin & streptomycin 
D. PRRSV inhibition correlates with inhibition of actin expression
Control (pen/strep)                          Plasmocin 250 ug/ml
Nalidixic acid 250 ug/ml                   Erythromycin 250 ug/ml 
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Table 2. Drug responses of primary alveolar porcine macrophages.
Drug treatment1  Expt. Percent PRRSV-positive cells relative to control
Plasmocin 250 ug/ml 1 0
 25 ug/ml 2 0
 125 ug/ml 3 28
 125 ug/ml 4 38
 125 ug/ml 5 0
 125 ug/ml 6 9
 50 ug/ml 6 80
 25 ug/ml 6 76
Nalidixic acid 250 ug/ml 1 21
 250 ug/ml 2 18
 250 ug/ml 3 20
 250 ug/ml 4 0
 250 ug/ml 5 13
Erythromycin 125 ug/ml 1 122
 250 ug/ml 2 98
 125 ug/ml 2 104
 62 ug/ml 2 106
1PAMs were treated with the indicated drug doses, testing responses in individual cultures against matched control (no drug) cultures for 
each experiment.
Table 3. Potentiation of cytokine-mediated inhibition of PRRSV replication by nalidixic acid: drug synergy with 
sub-optimal drug concentrations.
Expt. cells Treatment/Pretreatment1 PRRSV response2
1. PAMs Nalidixic acid (25 ug/ml) 81% of control
(Treatment) AK-2 (125 ng/ml) 74% of control
 AK-2 + Nalidixic acid 45% of control
2. PAMs Nalidixic acid (25 ug/ml) 107% of control
(Pretreatment) AK-2 (125 ng/ml) 145% of control
 AK-2 + Nalidixic acid 20% of control
3. PAMs Nalidixic acid (25 ug/ml) 114% of control
(Pretreatment) IFN-γ (400 ng/ml) 103% of control
 IFN-γ + Nalidixic acid 31% of control
4. MARC-145 Control 251 +/− 27 positive cells
(Pretreatment) Nalidixic acid (25 ug/ml) 221 +/− 20 positive cells
 AK-2 (62 ng/ml) 38 +/− 6 positive cells
 AK-2 + Nalidixic acid 10 +/− 4 positive cells
5. MARC-145 Control 363 +/− 30 positive cells
(Pretreatment) Nalidixic acid (25 ug/ml) 543 +/− 44 positive cells
 AK-2 (31 ng/ml) 166 +/− 42 positive cells
 AK-2 + Nalidixic acid 104 +/− 14 positive cells
6. MARC-145 Control 136 +/− 22 positive cells
(Pretreatment) Nalidixic acid (25 ug/ml) 164 +/− 55 positive cells
 IFN-γ (400 ng/ml) 68 +/− 1 positive cells
 IFN-γ + Nalidixic acid 40 +/− 10 positive cells
7. MARC-145 Control 514 +/− 17 positive cells
(Pretreatment) Nalidixic acid (25 ug/ml) 570 +/− 33 positive cells
 IFN-γ (200 ng/ml) 587 +/− 32 positive cells
 IFN-γ + Nalidixic acid 479 +/− 26 positive cells
8. MARC-145 Control 192 +/− 2 positive cells
(Pretreatment) Nalidixic acid (25 ug/ml) 188 +/− 33 positive cells
 IFN-γ (400 ng/ml)  114 +/− 4 positive cells
 IFN-γ + Nalidixic acid 75 +/− 2 positive cells
1Pretreatment consisted of 5 h incubation followed by removal of drugs and inoculation with PRRSV. For the treatment protocol, drugs 
were present throughout the virus exposure phase as well as during a one-h pretreatment period.
2PAM responses are reported as the percent infection relative to control cultures; MARC-145 cell responses are reported as mean total 
PRRSV-positive cells/culture +/− SD for duplicate wells.
24
Cafruny et al
Virology: Research and Treatment 2008:1 
Table 4. Cytotoxicity testing by trypan blue dye exclusion.
Expt. Cells Drug treatment No. or % dead cells/well*
1 PAM None 1%
  Plasmocin 250 ug/ml ∼50%
  50 ug/ml 1%
  25 ug/ml 1%
2 PAM None 37
  Plasmocin 250 ug/ml ∼20%
  125 ug/ml 12
  25 ug/ml 10
3 PAM None (Control) 6
  IFN-γ 400 ng/ml 3
  Nalidixic acid 25 ug/ml 2
  IFN-γ + Nalidixic acid 2
4 PAM None (Control) 5
  AK-2 125 ng/ml 3
  NA 25 ug/ml 2
  AK-2 + Nalidixic acid 3
5 PAM None 2
  Plasmocin 25 ug/ml 1
  Nalidixic acid 250 ug/ml 2
6 PAM None 27
  Plasmocin 25 ug/ml 19
  Nalidixic acid 250 ug/ml 31
7 MARC-145 None (Control) 34 +/− 9
  AK-2 125 ug/ml 16 +/− 6
  Nalidixic acid 25 ug/ml 12 +/− 6
  AK-2 + Nalidixic acid 16 +/− 2
8 MARC-145 None (Control) 4 +/− 6
  Plasmocin 250 ug/ml 4 +/− 1
  25 ug/ml 2 +/− 1
  2.5 ug/ml 1 +/−1
9 MARC-145 None (Control) 1 +/− 1
  Plasmocin 250 ug/ml 1 +/− 1
  25 ug/ml 2 +/−1
  2.5 ug/ml 2 +/− 1
10 MARC-145 None (Control) 8 +/− 4
  Plasmocin 250 ug/ml 8 +/− 1
  125 ug/ml 5 +/− 2
  50 ug/ml 6 +/− 4
11 MARC-145 None (Control) 11 +/− 4
  Nalidixic acid 250 ng/ml 9 +/− 4
  125 ng/ml 18 +/− 4
  62 ng/ml 11 +/− 8
*Dead cells were stained with trypan blue at about 22−24 h post-drug treatment for all experiments except #8 and #9, which were stained 
at 6 h post-drug treatment. For expts. #1 (all cultures) and 2 (Plasmocin 250 ug/ml), the% dead cells is given; for expt. #2 (control and lower 
Plasmocin doses) and all other experiments, the total dead cells per culture well are shown. MARC-145 cell results are mean +/− SD for 
duplicate wells. Field counts were assessed for all wells after crystal violet staining and no detectable differences were observed between 
drug-treated and control wells except for expts. #1 and 2, in which there was about 50% reduction in total PAMs at the highest concentration 
only (250 ug/ml) of plasmocin. Concentrations of drugs in combination were the same as when used individually within each experiment.
Inhibition of lactate 
dehydrogenase-elevation virus (LDV) 
replication by plasmocin
Primary peritoneal macrophages were LDV 
infected with or without Plasmocin in the culture 
medium. At 8 h p.i. the cells were fi xed and stained 
for LDV antigen. Plasmocin at 250 ug/ml 
completely inhibited LDV replication (no positive 
cells per well), and at 25 ug partially inhibited LDV 
replication (179 +/− 22 LDV-positive cells per 
well, versus 272 +/− 16 positive cells per well in 
the untreated control, mean +/− SD given for 
duplicate wells.
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Figure 2. Potentiation of the antiviral cytokine response by nalidixic acid.
A. Sub-optimal concentrations of nalidixic acid (25 ug/ml) and AK-2 (31 ng/ml) were used to reveal drug synergy. B. Partial resistance (arrows) 
in some cells after combined sub-optimal dosing with nalidixic acid and AK-2. Single-drug treatment results are shown for comparison. Scale 
bars = 50 um.
A. Nalidixic acid synergy with AK-2 
Control       AK-2 + Nalidixic acid 
Nalidixic acid only       AK-2 only
B. Partial PRRSV resistance in some cells after combined drug treatment at
sub-optimal concentrations
AK-2 only           Nalidixic acid only      AK-2 + Nalidixic acid
26
Cafruny et al
Virology: Research and Treatment 2008:1 
Discussion
These results demonstrate the ability of several 
quinolone-containing antibiotics to inhibit arteri-
virus replication. Antibiotic-mediated suppression 
of both PRRSV and LDV was observed, the former 
in both primary pig cells and the MARC-145 cell 
line, and the latter in primary mouse macrophages. 
Thus, the antiviral effects of certain quinolone 
antibiotics are expressed in at least three different 
cell types. The PRRSV responses were shown to 
be dose- and time-dependent, and selectivity of the 
quinolone effects was also observed.
Nalidixic acid is the prototype quinolone 
(Crump et al. 2003) and was investigated further, 
in combination with the antiviral cytokines AK-2 
and IFN-γ, employing pretreatment with sub-
optimal drug doses to search for antiviral synergy. 
In both MARC-145 cells and primary pig macro-
phages, nalidixic acid was found to potentiate the 
antiviral effects of AK-2 and IFN-γ, even when 
single-drug exposures under these conditions failed 
to inhibit viral permissiveness. The mechanism is 
not clear, but potentiation under conditions in 
which the nalidixic acid concentration used failed 
to inhibit virus suggest the possibility of drug 
synergy, in which the combined activity is greater 
than the sum of individual activities (Wingard et al. 
1991). In addition, exposure to the drug combina-
tions induced partial resistance to virus replication 
in some cells.
Quinolones inhibit bacterial growth by interfer-
ing with the replication fork (acting on DNA 
gyrases and topoisomerases). The mechanism by 
which quinolones mediate antiviral effects in mam-
malian cells is not known from the present work, 
but does not appear to be related to direct cellular 
cytotoxicity, since dye-exclusion and cell count 
studies failed to support a detectable cytotoxic 
effect at the drug concentrations used. Furthermore, 
post-treatment by 3–6 h relative to virus inocula-
tion was less effective than simultaneous treatment, 
indicating that an early stage in virus infection was 
the target rather than a general cytotoxicity in the 
cultured cells.
AK-2 and IFN-γ exert their antiviral effects 
by activating an antiviral gene program, consis-
tent with the antiviral effi cacy of these drugs 
during pretreatment followed by drug wash-out 
in our studies. Synergy (defi ned by combined 
activity greater than the sum of independent 
activities; Wingard et al. 1991) of nalidixic acid 
in combination with AK-2 or IFN-γ during our 
pretreatment strategies, suggests that this quino-
lone may also target viral permissiveness. Addi-
tional studies would be of interest to discriminate 
between the possibilities of a metabolic toxicity 
with antiviral side-effects and a more conven-
tional activation of viral resistance by combina-
tion drug treatment.
The arteriviruses PRRSV and LDV are both 
dependent on an intact cytoskeleton for replication, 
and actin expression appears to be required for 
PRRSV replication, since inhibition of actin by 
cytochalasin D impairs the ability of PRRSV to infect 
cultured target cells (Cafruny et al. 2006). The pres-
ent study demonstrated a correlation between actin 
and virus inhibition by the quinolone-containing 
antibiotics, although exposure to penicillin, 
streptomycin, or erythromycin failed to inhibit virus 
or actin expression. The cytoskeleton is a potentially 
important target in the identifi cation of new antiviral 
molecules (Dohner and Sodeik, 2005); while it is 
intriguing to speculate that actin may be involved in 
the antiviral mechanisms of these quinolones, further 
studies are needed to address this possibility.
Previous studies have shown that the aminogly-
coside hygromycin B inhibits mouse hepatitis virus 
(Macintyre et al. 1991), the macrolide bafi lomycin 
inhibits African swine fever virus in porcine mac-
rophages due to inhibition of the endosomal/lyso-
somal pump (Natale and McCullough, 1998), and 
rifampin inhibits poxviruses via effects on the viral 
envelope and protein assembly (Subak-Sharpe 
et al. 1969; Zhang and Moss, 1992; Sodeik et al. 
1994). Coumermycin, like the quinolones an 
inhibitor of bacterial DNA gyrase, also inhibits 
retrovirus replication (Varnier et al. 1984). Thus, 
the present results add to the evidence that antibi-
otics may have antiviral activity, and furthermore 
demonstrate the ability of an antibiotic to potenti-
ate antiviral cytokine effects, providing a new 
avenue for the study of antiviral mechanisms. 
These results also have implications for antiviral 
treatment or prevention strategies, utilizing com-
bination therapy with the benefi t of lowered toxic-
ity, and particularly in vivo where the internal 
cytokine environment may help trigger antiviral 
responses to sub-optimal quinolone levels. While 
additional studies would be needed to determine 
clinical relevance, lipid-soluble antibiotics become 
concentrated in alveolar macrophages (Hand et al. 
1984; Hand and King-Thompson, 1989), and cip-
rofl oxacin levels of about 35 ug/ml have been 
reported in alveolar macrophages after oral dosing 
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of humans (Gotfried et al. 2001), suggesting the 
potential for in vivo activity of quinolone deriva-
tives against alveolar macrophage-tropic viruses 
such as PRRSV.
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